Alternative names: Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis is a serious, progressive disease of the lungs in which lung tissue becomes scarred and thickened, resulting in increasingly impaired lung function and difficulty breathing.
Pulmonary Fibrosis usually affects those over the age of 50, men more often than women, and smokers much more often than non-smokers. Overall, this disease affects about 1 person in every 5,000.
There are many possible causes of the scarring that causes Pulmonary Fibrosis, but in any particular case the specific cause is usually unknown. Causes include:
Research is suggesting that development of the disease my be triggered by tobacco smoke or certain viral infections.
This scarring occurs between the air sacs in the lungs, making it more difficult for inhaled oxygen to pass from the lungs into the bloodstream.
People who work in jobs that involve exposure to airborne particles or toxins are at risk, as well as those who take certain medications. Genetics also plays a role, with about 1-in-20 patients having another family member with the condition.
Diagnosis involves discussing recent symptoms, reviewing the patient's medical and other history to look for possible risk factors, listening to the lungs with a stethoscope as the patient breathes in and out. If Pulmonary Fibrosis is suspected then various diagnostic tests can be performed:
The lung damage that occurs as a result of Pulmonary Fibrosis cannot be reversed or repaired, leaving a lung transplant as the only real treatment option. Unfortunately, donor lungs are rare. Medications can be used to help reduce the symptoms and slow their progress.
Commonsense lifestyle changes include stopping smoking, eating healthy foods, and exercising regularly, as much as the condition permits.
Patients with rapidly worsening symptoms, such as severe shortness of breath, may receive supplemental oxygen to help with breathing (oxygen therapy), or be placed on a mechanical ventilator and given antibiotics or corticosteroids to reduce inflammation. Azathioprine and cyclophosphamide also reduce inflammation by suppressing the immune system. Pirfenidone and Nintedanib reduce the rate of scarring.
New drugs are being developed over time in order to improve the lives and life expectancy of patients.
The prognosis varies by person, but life expectancy after diagnosis is usually around 3 to 5 years. Some people become very ill very quickly, while others have less severe symptoms that worsen slowly. In some cases, symptoms can remain the same for years.
Possible complications include:
See a doctor if you experience unexplained breathlessness or have had a cough for more than 3 weeks.
People often ignore breathlessness, putting it down to getting old or being out of shape. As Pulmonary Fibrosis progresses, even light activity (or no activity at all) can cause shortness of breath. Breathlessness is not normal, except after significant exercise.
A chronic dry, hacking cough is characteristic of Pulmonary Fibrosis.
Joint pain is one possible symptom of Pulmonary Fibrosis.
The main symptom of Pulmonary Fibrosis is shortness of breath, with or without exertion, made worse by even slight exertion.
Your body is a highly complex, interconnected system. Instead of guessing at what might be wrong, let us help you discover what is really going on inside your body based on the many clues it is giving.
Our multiple symptom checker provides in-depth health analysis by The Analyst™ with full explanations, recommendations and (optionally) doctors available for case review and answering your specific questions.